Haldol Related Published Studies
Well-designed clinical trials related to Haldol (Haloperidol)
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. [2008.11]
Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. [2008.07]
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. [2008.06]
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. [2008.05.09]
Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting. [2008.05]
Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting. [2008.05]
The prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. [2008.05]
The timing of haloperidol administration does not affect its prophylactic antiemetic efficacy. [2008.05]
Adjunctive Haloperidol Prophylaxis Reduces Postoperative Delirium Severity and Duration in At-Risk Elderly Patients. [2008.03]
Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. [2008.03]
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. [2008.02.15]
Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. [2008.02]
Low-dose haloperidol prevents post-operative nausea and vomiting after ambulatory laparoscopic surgery. [2008.02]
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. [2008.02]
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. [2008.02]
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. [2008.02]
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. [2008.01.05]
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. [2008.01]
A randomized, controlled prospective trial of zolpidem and haloperidol for use as sleeping agents in pediatric burn patients. [2008.01]
Risperidone versus haloperidol in children and adolescents with AD : A randomized, controlled, double-blind trial. [2007.12.13]
Amoxapine as an antipsychotic: comparative study versus haloperidol. [2007.12]
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder : An open label maintenance study. [2007.11.19]
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. [2007.11]
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German research network on schizophrenia. [2007.11]
Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. [2007.10.27]
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. [2007.09]
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. [2007.09]
The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting. [2007.08]
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial. [2007.07.25]
Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol. [2007.07]
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. [2007.06]
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. [2007.05]
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. [2007.03]
A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania. [2007.03]
Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. [2007.03]
Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. [2007.02]
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. [2006.11]
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. [2006.10]
Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. [2006.10]
Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. [2006.10]
The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. [2006.09]
Olanzapine and haloperidol in first episode psychosis: two-year data. [2006.09]
Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. [2006.08]
Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. [2006.07]
Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. [2006.05]
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. [2006.04]
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. [2006.03]
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. [2006.03]
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. [2006.03]
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. [2006.01.15]
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. [2006.01.01]
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. [2006]
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. [2005.12]
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. [2005.11]
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. [2005.10.15]
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. [2005.10]
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. [2005.10]
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. [2005.10]
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. [2005.09]
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. [2005.07]
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. [2005.06]
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. [2005.06]
Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. [2005.06]
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. [2005.05]
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. [2005.05]
Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. [2005.04]
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. [2005.04]
Effects of haloperidol on reactions to smoking cues in humans. [2005.03]
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. [2005.02]
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. [2005.01]
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. [2005.01]
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. [2005.01]
Well-designed clinical trials possibly related to Haldol (Haloperidol)
Interventions for psychotic symptoms concomitant with epilepsy. [2008.10.08]
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. [2008.06]
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. [2008.05]
Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms. [2008.05]
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). [2008.04.01]
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. [2008.04]
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. [2008.04]
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. [2008.04]
Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. [2008.04]
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. [2008.03.29]
Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. [2008.03.15]
Modulation of human motor cortex excitability by quetiapine. [2008.03]
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. [2008.02]
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. [2008.02]
Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomized trial. [2008.01]
Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli. [2008.01]
Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. [2008]
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]
Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia. [2007.12]
[Comparative observation on acupuncture and western medicine for treatment of minimal brain dysfunction] [2007.12]
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. [2007.11]
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. [2007.11]
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. [2007.10]
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. [2007.09]
A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. [2007.08]
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. [2007.08]
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. [2007.06.30]
Quetiapine for acute mania in bipolar disorder. [2007.05.15]
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. [2007.01]
|
